Abstract: Lenalidomide, a potent immunomodulatory agent, has been demonstrated to have significant efficacy in indolent B-cell lymphoma treatment. However, its adoption into clinical practice remains a subject of debate for other subtypes of lymphoma, particularly aggressive B-cell lymphoma. This controversy stems from the intricate classification of lymphoma subtypes, coupled with disease heterogeneity from genetic abnormalities and clinical manifestations. To address these challenges, the Lymphoma Committee of China Anti-Cancer Association has developed a comprehensive expert consensus on the clinical utilization of lenalidomide for lymphoma, based on pivotal prospective clinical trials and real-world evidences. The consensus comprehensively introduces lenalidomide monotherapy and combination regimens, delineating their efficacy across common lymphoma subtypes. Furthermore, it outlines recommendations for administration, dose adjustment in response to adverse effects and special populations, as well as precautions. This expert consensus provides physicians with a robust framework for personalized clinical applications of lenalidomide in the management of lymphoma with safety and effectiveness.